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1. Introduction 
Human immunodeficiency virus (HIV), the causative agent of Acquired immunodeficiency 
syndrome (AIDS) is found in pandemic proportions globally (Osmond and Dennis, 1994). 
HIV is a scourge, progressing and causing devastation to lives and the healthcare system 
worldwide (Carpenter et al, 2000). HIV accounted for 38.6 million infections worldwide at 
the end of 2005. As at 2003, there were about 5.0 million people infected with HIV in 
Nigeria, giving a national prevalence rate of 5.0% (Federal Ministry of Health, 2004). 
Infection with HIV occurs through the transfer of infected blood, semen, vaginal fluid, pre-
ejaculate, or breast milk. The four major routes of transmission are unprotected sexual 
intercourse, contaminated blood transfusion, breast milk, transmission from an infected 
mother to her baby at birth (vertical transmission) (http://en.wikipedia.org/wiki/HIV). 
Millions of lives are saved each year through blood transfusion. Nonetheless people have a 
risk of becoming infected with HIV through transfusion of infected blood and blood 
products. Transmission of HIV and other blood-borne infections can occur during 
transfusion of blood components (ie, whole blood, packed red cells, fresh-frozen plasma, 
cryoprecipitate, and platelets) derived from the blood of an infected individual (Donegan et 
al, 1994). Depending on the production process used, blood products derived from pooled 
plasma can also transmit HIV and other viruses, but recombinant clotting factors cannot 
(Berkman et al, 2000) This chapter discusses the transmission of HIV through blood 
products; prevalence; risk of acquisition through blood transfusion, the current estimated 
safety of blood components and control measures.  
2. HIV infection transmitted during blood transfusion 
HIV infection resulting from blood transfusion has been documented repeatedly since the 
first case report in late 1982 (Curran et al, 1984). HIV transmission through unsafe blood 
accounts for the second largest source of HIV infection in Nigeria (Federal Ministry of 
Health, 2009). Not all Nigerian hospitals have the technology to effectively screen blood and 
therefore there is a risk of using contaminated blood. The Nigerian Federal Ministry of 
Health have responded by backing legislation that requires hospitals to only use blood from 
the National Blood Transfusion Service, which has far more advanced blood-screening 
technology (Nigeria Exchange, 2008).  
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3. Prevalence of HIV infection among blood donors 
The prevalence of HIV infection among blood donors varies from one geographical location 
to another and can provide a reasonable ‘proxy’ for HIV infection levels in a larger adult 
population (WHO/UNAIDS, 2000).    
As of January 2004 to December 2008, a total of 15,569 blood donors have been screened for 
HIV antibodies in Jos University Teaching Hospital of which 1070 were positive, giving a 
seroprevalence rate of 6.9% (Egesie et al, 2011) as shown in table 1. A fluctuating course in 
the seroprevalence of HIV among blood donors was observed for the period under review. 
This finding is in agreement with the study by Hassan et al (2008) in Kaduna, North-western 
Nigeria and the work by Fasola et al (2009) in Ibadan, South-west Nigeria. 
 
Year  Total number screened Positive  Negative  
2004 1473(100%) 95(6.4%) 1378(9.3%) 
2005 4547(100%) 294(6.5%) 4253(93.5%) 
2006 3299(100%) 184(5.6%) 3115(94.4%) 
2007 1443(100%) 61(4.2%) 1382(95.8%) 
2008 4807(100%) 436(9.1%) 4371(90.9%) 
Grand 
Total 
15,569 1070 14499 
Table 1. Blood donors screened for human immunodeficiency virus in Jos 
This prevalence rate obtained in Jos is higher than the 0.08% found by Gupta et al (2004) in 
their study among Indian blood donors. It is also much higher than the 0.004% found by 
Bhatti et al (2007) in Karachi among Pakistani donors, and the 0.00009% found by Khan et al 
(2002) in Peshawar among Pakistani donors. These prevalence rates are shown in table 2 
below. 
 
Location  Prevalence (%)
Peshawar (Pakistan) 0.00009 
Karachi (Pakistan) 0.004 
India 0.08 
Kenya  5.8 
Tanzania  8.7 
Table 2. Prevalence of HIV among blood donors in other parts of the world 
The HIV infection rate in this study is also higher than 1.0% in the work of Ejele et al (2005) 
in Port Harcourt, South-south Nigeria; the 3.1% found by 
Fiekumo et al (2009) in Osogbo, South-west Nigeria; the 3.9% found by Esumeh et al (2003) 
in another study in Benin city, South-south Nigeria; the 5.8% in the works of Chikwem et al 
(1997) in Maiduguri, North-eastern Nigeria and that of Abdalla et al (2005) among Kenyan 
donors. Furthermore, Fasola et al (2009) found an infection rate of 7.7% among their donors 
in Ibadan, Southwestern Nigeria while Matee et al (1999) in their work among Tanzanian 
donors, and Kagu et al (2005) in their work in Nguru, North-eastern Nigeria found an HIV 
infection rate of 8.7%. (Table 3) 
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Location  Prevalence (%)
Port Harcourt 1.0 
Osogbo  3.1 
Benin City 3.9 
Maiduguri  5.8 
Ibadan  7.7 
Nguru  8.7 
Table 3. Prevalence of HIV among blood donors in other parts of Nigeria 
The wide differences in the HIV infection rate among the blood donors in the different 
regions within Nigeria, and even those outside Nigeria may be due to the differences in 
geographical locations, age range of donors, sample sizes, the period of time the studies 
were carried out, and the different socio-cultural practices such as sexual behavior, marriage 
practices, circumcision, scarification, tattooing etc which take place in these regions. Access 
to healthcare services and the laboratory test reagent kits used may also be contributory 
factors. 
The high prevalence of HIV infection among blood donors has heightened the problems of 
blood safety in Nigeria. The implication of HIV in voluntary blood donors is the risk of 
transmission of these infections to recipients of blood and blood products as safe blood will 
be more difficult to get. . It also reflects the prevalence of the infection in the general 
population from which these blood donors are drawn.  
An unsafe blood transfusion is very costly both in terms of human and economic costs. 
Morbidity and mortality resulting from the transfusion of infected blood have far-reaching 
consequences, not only for the recipients themselves, but also their families, their 
communities and the wider society (WHO, 2002 and 2007). Since a person can transmit HIV 
infection during the asymptomatic phase, it can contribute to an ever-widening pool of HIV 
infection in the wider population. From the study in Jos-Nigeria, it was observed that HIV 
infection was found among the 20-39 years age range. This finding is in agreement with the 
study by Ejele et al (2005) in which higher prevalence of transfusion-transmissible viral 
infections were observed among youths. This observation is worrisome since the most 
productive and economically viable age group of the populations is worst hit. There is the 
urgent need for renewed intensification of preventive programmes aimed at reducing the 
scourge of this infection (Olokoba et al, 2010). 
In some resource-rich countries, testing of donated blood for HIV antibodies was not 
immediately initiated for a variety of reasons. France began HIV antibody testing in June 
1985, Canada began testing in November 1985, and Switzerland began testing in May 1986. 
Germany inconsistently tested plasma products between 1987 and 1993, as did Japan in 1985 
and 1986. These delays led to criminal investigations in France, Germany, Switzerland, and 
Japan, which in some cases led to criminal conviction of those persons found to be 
responsible (Weinberg et al, 2002). At least 20 countries initiated compensation programs for 
some individuals infected by transfusion of HIV-contaminated blood and blood products. 
4. Risk of acquisition of HIV infection through blood transfusion and 
estimated safety of components  
The risk of HIV transfusion through infected blood products exceeds that of any other risk 
exposure. Ninety percent of recipients transfused with HIV antibody-positive blood were 
www.intechopen.com
 
HIV-Infection – Impact, Awareness and Social Implications of Living with HIV/AIDS 236 
found to be HIV infected at follow-up (Donegan et al, 1994). The 90% probability of 
seroconversion is independent of the age or sex of the recipient, the reason for transfusion, 
and the type of component transfused (excluding washed red blood cells, which transmit 
HIV at a lower rate) (Donegan et al, 1990).   
HIV infectivity of red blood cell components that were not washed before transfusion 
decreases as storage time increases. HIV-contaminated red blood cells stored for <8 days are 
96% infectious, whereas those stored for >3 weeks are 50% infectious (Donegan et al, 1994). 
The level of a donor's viremia at the time of donation is also an important determinant of 
HIV transmission risk, but no other donor characteristics have been found to affect 
transmission (Busch et al, 1996).  Of all transfused patients, half die within 6 months after 
transfusion from the underlying disease that necessitated the transfusion. Currently, cases 
involving transfusion of HIV-positive blood do not increase the overall 1-year post 
transfusion mortality rate of recipients in the United States (Donegan et al, 1994). In Zaire, 
however, patients transfused with HIV-positive blood are 31% more likely to be dead 1 year 
after transfusion than are patients transfused with HIV-negative blood (Colebunders et al, 
1991). This difference is unexplained but emphasizes the importance of screening blood for 
HIV in developing countries.  
HIV disease due to transfusion progresses in the recipient at rates comparable to those in 
individuals infected for similar duration but by other routes (Donegan et al, 1986). One 
report found that a transfusion recipient may develop AIDS more rapidly if the infected 
blood component comes from a blood donor who develops AIDS soon after the time of the 
blood donation. Other analyses, however, do not confirm this finding.(Busch et al,1990) It is 
more likely that host factors, particularly the recipient's age and immune status, and 
perhaps other as-yet-undefined cofactors influence the progression to AIDS (Operskalski et 
al,1995) The mean time of progression to AIDS is estimated to be 8.2 years for adult 
transfusion recipients who receive no antiretroviral therapy, with a cumulative prevalence 
of 20% having AIDS 5 years after infection (Medley et al, 1987). This progression rate may be 
overestimated, and the mean time to AIDS development underestimated, because these 
values are based primarily on data from recipients identified because they developed AIDS 
or because they received blood from donors who subsequently developed AIDS. The data 
exclude many donors and recipients who have not been identified because they remain 
asymptomatic.  
Transmission of HIV by transfusion has decreased in developing countries since the 
initiation of voluntary deferral of donors at risk for HIV infection and routine HIV antibody 
testing of all donations. Continued improvement in donor recruitment practices, donor 
education, donor screening, and blood testing has resulted in continued decreases in the risk 
of transfusion transmission of HIV. In 1995, the risk in the United States of HIV-1 
transmission per unit transfused was estimated to be between 1 in 450,000 and 1 in 
660,000.(Schreiber et al 1996, Lackritz et al,1995). By 2003, this estimated risk had decreased 
to between 1 in 1.4 million and 1 in 1.8 million units (Busch et al, 2003).  
HIV antibody tests fail to identify HIV-infected blood donated by HIV-infected persons who 
have not yet seroconverted. Exclusion of donors is voluntary. Interviews with HIV 
antibody-positive donors reveal that most recognize their risk but fail to exclude 
themselves.(Cleary et al, 1988) As a result, laboratory efforts to eliminate HIV-infected 
donors have continued and testing has improved. Currently, HIV antibody tests detect both 
HIV-1 and HIV-2 and detect antibody approximately 22 days (the "window period") after 
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the viremic phase of HIV infection begins. Antigen testing for p24, mandated by the U.S. 
Food and Drug Administration (FDA) in 1996, shortened the window period to 
approximately 16 days. The nucleic acid amplification test (NAT), which detects HIV-1 RNA 
in minipools (16-24 donation samples/pool), was introduced in the United States in 1999 
and further reduces the window period of potential HIV transmission to 11 days 
(Goodnough et al, 2003). As of early 2003, three transfusion recipients are known to have 
become HIV infected by transfusion of HIV antibody-negative, p24 antigen-negative, and 
HIV NAT-negative blood from two different blood donors (among 25 million donations) 
(www.cbsnews.com/stories/2002/07/19/health/main/515694.shtml)  
The global perspective is not as bright as that described for resource-rich countries. 
Worldwide, 75 million units of blood are estimated to be donated annually, compared with 
1.5 million donations in Nigeria. Of the 191 WHO member states, only 43% test blood for 
HIV, hepatitis C, and hepatitis B viruses. Transfusion-transmitted HIV infection is thought 
to account for 80,000-160,000 infections annually, contributing 2-4% of all cases of HIV 
transmission (Bharucha, et al, 2002). Only 20% of the world's supply of safe blood is 
available to countries with 80% of the world's population. 
5. Control measures 
Significant progress has been made globally by a number of countries in reducing HIV 
prevalence through sound prevention effort. HIV prevention still remains the most effective 
strategy towards addressing the global AIDS pandemic. It is for this reason that various 
groups and organizations have instituted foundations and committee as a necessary step 
towards that goal. (National Agency for the Control of AIDS, 2010) 
In Nigeria, various preventive strategies are being carried out. One of the components of 
such preventive strategies is the blood safety programme. This is particularly important in 
view of the fact that the risk of transmission of HIV through infected blood is virtually 100% 
(Roberts et al, 1994). 
Transmission of HIV through infected blood and blood products accounts for 
approximately 10% in African region (Mvere, 2002) and  the second largest source of HIV 
infection in Nigeria (Federal Ministry of Health, 2009). 
Blood safety remains an issue of major concern in transfusion medicine in developing 
countries like Nigeria where national blood transfusion services, appropriate infrastructure, 
trained personnel and financial resources are inadequate due to poor budgetary allocation 
to the health sector. Inadequate funding for HIV testing is only a part of the problem. 
Specific issues that urgently need to be addressed include the lack of a sufficient volunteer 
blood donor pool, inadequate blood donor screening information, counseling, and 
confidentiality.  
Implementation of standardized and monitored test manufacturing practices, inclusion of 
test validation procedures, ongoing staff training, and continuous internal and external 
quality assessment programs are all necessary components of an effective program to 
prevent transmission. Moreover, transfusion practices must be monitored locally so that 
HIV transmission from unnecessary transfusions does not occur. 
Since blood transfusion is an important part of modern medicine, safety of blood and blood 
products remains a global issue. The continuous monitoring of the magnitude of transfusion 
transmissible infections in blood donors is important for estimating the risk of transfusion 
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and optimizing infectious diseases transmission (Tessema et al, 2010).  Strict selection of 
blood donors with the emphasis on getting voluntary donors and comprehensive screening 
of blood donors for HIV and other transfusion transmissible infections using standard 
methods are highly recommended to ensure the safety of blood for recipient.  We therefore 
recommend the screening of all prospective blood donors for all transfusion transmissible 
infections. A strict selection criterion for blood donors to exclude those who have multiple 
sexual partners and those who engage in high risk behaviour and also that blood 
transfusion should be given only when absolutely indicated. 
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